Search STLN
The Oncology Institute, Inc.
NasdaqCM · CIK 1799191
Last close6.35
Daily change+0.13 (2.17%)
10 Years gain-34.54%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
STLN · STANDARD
SIC 8011 · Services-Offices & Clinics of Doctors of Medicine · Fiscal year end 1231
Fundamental
50.9Momentum
96.2Acceleration
97.7Confidence
75.0Annual Revenue6
Quarterly Revenue17
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth23.8 / 25
Quality15.8 / 25
Capital Efficiency0.0 / 20
Balance Sheet8.7 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 9.2359 percentage points.
ROIC expansionROIC improved by 10.0167 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 33.6356%.
Key Metrics
Revenue Growth TTM42.14%OK
Revenue CAGR 3Y25.81%OK
Gross Marginn/aMISSING
Operating Margin-5.38%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-51.74%OK
Incremental Operating Margin 3Y2.78%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y33.64%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $502.73M | n/a | -$36.08M | -$24.59M | -$27.79M | n/a | -7.18% | -5.53% | -75.85% | 92.39M |
| 2025 FY Dec 31, 2024 | $393.41M | n/a | -$60.12M | -$26.54M | -$30.33M | n/a | -15.28% | -7.71% | -87.91% | 75.04M |
| 2024 FY Dec 31, 2023 | $324.24M | n/a | -$77.02M | -$36.32M | -$40.88M | n/a | -23.75% | -12.61% | -63.72% | 73.75M |
| 2023 FY Dec 31, 2022 | $252.48M | n/a | -$81.95M | -$61.76M | -$67.29M | n/a | -32.46% | -26.65% | -108.66% | 80.61M |
| 2022 FY Dec 31, 2021 | $203.00M | n/a | -$45.86M | -$32.68M | -$35.53M | n/a | -22.59% | -17.5% | -256.05% | 66.23M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $565.09M | sum latest 4 fiscal quarters Revenue | OK | 0001799191-26-000017, 0001799191-25-000036 |
| Revenue Growth TTM | 42.14% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001799191-26-000017, 0001799191-25-000036 |
| Revenue CAGR 3Y | 25.81% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001799191-26-000007 |
| Revenue CAGR 5Y | 21.8% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001799191-26-000007 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001799191-26-000017, 0001799191-25-000036 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -5.38% | Operating Income / Revenue | OK | 0001799191-26-000017, 0001799191-25-000036 |
| ROIC | -51.74% | NOPAT / Average Invested Capital | OK | 0001799191-26-000017, 0001799191-25-000036 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001799191-26-000017 |
| Current Ratio | 1.36x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.51x | (Cash + Short-term Investments) / Total Debt | OK | 0001799191-26-000017 |
| Revenue per Diluted Share | $5.48 | Revenue / Diluted Shares | OK | 0001799191-26-000017, 0001799191-25-000036 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |